Your browser is using an outdated encryption protocol. On or before July 2018, you may no longer be able to access RunSignUp and other websites unless you update your browser.
Location: Saint Louis, MO US 63146 Directions
Type: Run or Run/Walk

Children Under the Age of 5 Do Not Need to Register.

Event Time Price Details
STL Cure Sarcoma 6K Run/Walk 2018
7:30AM CDT - 12:30PM CDT
Registration Opens May 14, 2018 at 9:59am CDT
Creve Coeur Park - Tremayne Shelter
13725 Marine Ave
Saint Louis, MO US 63146

We are pleased to announce the 6th Annual STL Cure Sarcoma 6K Run/Walk will be held on Sunday, October 7, 2018, at the Creve Coeur Park - Tremayne Shelter 13725 Marine Avenue, St. Louis, MO  63146.  This is more than just a race!  We welcome competitive runners, non-competitive walkers and non-walkers alike.  If you do not want to participate in the actual race, we encourage you to still register to enjoy lunch, music, and a good cause!  Please come out to show all of the families effected by this very rare disease that they are not alone!

Your registration includes access to:

  • Chip timed race provided by Big River Running Company
  • Lunch provided after the race
  • Event T-shirt
  • Children's activities: Bounce houses, face painting and balloon artists
  • Race bag with goodies
  • DJ music and fun
  • Basket Raffle/Silent Auction

**Bring the whole family and your lawn chairs to enjoy the morning with us after the race!

Check-in & On-site registration begin at 7:30 AM
Chip-timed race begins at 9:30 AM


**Children 5 and under are FREE, but must register or email by September 25th if they would like an event t-shirt.

Registration through July 31: $25

August 1 - August 31: $30

September 1 - September 25: $35 (Last day to register and guarantee you get a T-shirt)

September 26 - October 5: $40

Same Day Registration: $40 (must arrive by 8:00 AM and t-shirts can NOT be guaranteed, we highly recommend registering in advance online)


Race Contact Info

If you have any questions about this race, click the button below.

Race Sponsor

We are very proud to announce that ALL of the net funds raised for this event have always been and will continue to be dedicated strictly to Sarcoma Research.  Fifty percent of funds raised will benefit the Sarcoma Research Grant Fund through Sarcoma Foundation of America.  These research grants are carefully selected and awarded to Sarcoma Researchers nationwide each year. The other 50% will benefit Dr. Brian Van Tine's Sarcoma research lab with Siteman Cancer Center at Washington University School of Medicine.  Please see a description of both of these wonderful organizations below:

Sarcoma Foundation of America is the leading voice for sarcoma patients, survivors and those who care about them. Since 2000, we have worked tirelessly to advocate for increased research to find new and better therapies with which to treat patients with sarcoma.  Sarcoma Foundation of America has funded over $7 million in translational research to help eradicate sarcoma, collaborating with many of the most promising minds in sarcoma research. 

Sarcoma Foundation of America also provides a voice to those individuals affected by this rare forgotten cancer through research advocacy and patient education.

Visit for more information and other ways to get involved.

Dr. Brian Van Tine’s Sarcoma Research at Siteman Cancer Center:

We study cancer metabolism using metabolomics to develop novel therapeutic strategies for rare tumors. Sarcomas are group of over 100 types of tumors of mesenchymal origin that can be divided into 2 categories: soft tissue sarcomas and bone sarcomas. We have demonstrated that argininosuccinate synthase 1 (ASS1) is lost in 88% of all sarcomas. This is an exploitable biomarker that correlates with poor prognosis for sarcoma. When ASS1 is not expressed, arginine becomes an essential amino acid that must be delivered by the diet. We are testing whether the ASS1-deficiency of sarcomas may be exploited using the arginine-lowering agent, pegylated arginine deiminase (ADI-PEG20) in vitro and in animal models. By exploiting autophagy induction, we hope to cause cell death using this agent in combination with others. In addition, we have identified other duel metabolic therapies that can be used instead of chemotherapy that also lead to cell death. Finally, we are launching an omics project in angiosarcoma this year to identify new targets for therapy by looking at the metabolome, phosphor-proteome, and DNA and RNA genome of patients.

All proceeds benefit: